Debiopharm, Sigma-Tau Acute Heart Failure Candidate Delivers Strong Phase IIa
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class luso-inotropic agent improved systolic and diastolic functions in patients with decompensated heart failure.
You may also be interested in...
Debiopharm Files Sanvar In France
Swiss-based Debiopharm is seeking European marketing partners for its somatostatin analog Sanvar (vapreotide acetate), the company said July 24
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.